The USP has submitted to CMS its Medicare Rx drug benefit model guidelines that Part D drug plans can use for formulary development during the 2007 benefit year. Version 2.0 of the guidelines reduced the number of unique drug categories and classes from 146 to 133 and increased the formulary key drug types from 118 to 141.
USP releases Medicare Rx model guidelines
The USP has submitted to CMS its Medicare Rx drug benefit model guidelines that Part D drug plans can use for formulary development during the 2007 benefit year. Version 2.0 of the guidelines reduced the number of unique drug categories and classes from 146 to 133 and increased the formulary key drug types from 118 to 141. The revision process will be ongoing to allow greater involvement by stakeholders, according to USP. To access the model guidelines and track the revisions, go to http://www.usp.org/healthcareInfo/mmg/phase2/.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.